ZBH
60
-2
PNW
66
3
ICE
59
-3
NWSA
62
2
XOM
47
5
IR
63
3
EQIX
60
-2
MS
74
-2
AXP
66
2
COF
55
-3
GM
65
-3
LLY
39
9
TDC
75
4
QCOM
48
-7
EQT
59
2
ORLY
53
-3
NOV
58
3
IBM
54
4
HUM
48
6
ADP
64
2
ZBH
60
-2
PNW
66
3
ICE
59
-3
NWSA
62
2
XOM
47
5
IR
63
3
EQIX
60
-2
MS
74
-2
AXP
66
2
COF
55
-3
GM
65
-3
LLY
39
9
TDC
75
4
QCOM
48
-7
EQT
59
2
ORLY
53
-3
NOV
58
3
IBM
54
4
HUM
48
6
ADP
64
2
Financhill
Back

Sarepta Therapeutics 10K Form

Sell
31

SRPT
Sarepta Therapeutics

Last Price:
110.51
Seasonality Move:
16.38%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive SRPT News And Ratings

See the #1 stock for the next 7 days that we like better than SRPT

SRPT Financial Statistics

Sales & Book Value

Annual Sales: $1.24B
Cash Flow: $-107.96M
Price / Cash Flow: 0
Annual Sales: $12.79
Price / Book: 8.19

Profitability

EPS (TTM): 1.54000
Net Income (TTM): $121.85M
Gross Margin: $1.09B
Return on Equity: 12.48%
Return on Assets: 3.67%

Sarepta Therapeutics Earnings Forecast

Key Sarepta Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 28 years for SRPT is 87.91%.
  • The Selling, General & Administrative Expenses for SRPT have been equal to 38.76% of Gross Profit Margin.
  • The Research & Development expenses have been 70.57% of Revenue.
  • The Interest Expense is -4.11% of Operating Income.
  • The Net Earning history of SRPT is -43.11% of Total Revenues.
  • Per Share Earnings over the last 28 years have been positive in 14 years.

Sarepta Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: SRPT
CUSIP: 803607
Website: sarepta.com

Debt

Debt-to-Equity Ratio: 1.01
Current Ratio: 3.84
Quick Ratio: 2.45

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 8.45

SRPT Technical Analysis vs Fundamental Analysis

Sell
31
Sarepta Therapeutics (SRPT) is a Sell

Is Sarepta Therapeutics a Buy or a Sell?